2021-04-07, -, Double Bond Pharmaceutical B, Årlig, 0,00. 2021-04-07, -, ESEN eSports, Årlig, 0,00. 2021-04-07, 2021-04-13, Footway Group Pref, Kvartal, 2,00.

Double Bond Pharmaceutical company which develops and commercialises innovative first-in-class approaches for treatment of cancers.

Our mission is to bring value to every patient by maximizing the capacity of some of the most effective medicines known and make them even better. Our vision is that medicines work best when they are active in the right place in the body at the right time, and this is exactly where we make them be. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. Double Bond Pharmaceutical International AB is a manufacturer of pharmaceutical preparation. The company is located in Uppsala, Sweden. Double Bond Pharmaceutical International AB is a pharmaceutical company, which engages in developing and commercializing approaches for treatment of cancers, infections, autoimmune diseases, and Double Bond Pharmaceutical is a fast growing pharmaceutical company that develops and commercializes innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases Double Bond Pharmaceutical International AB is a pharmaceutical company.

14.00 i företagets lokaler på Virdings Allé 32 B, 754 50 Uppsala Besöksadress: Västra Ingången av Uppsala Business Park, Rapsgatan 7, Uppsala Double Bond Pharmaceutical AB (556959-2982). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar. Double Bond Pharmaceutical, DBP, är ett läkemedelsbolag. Störst inriktning innehas mot behandling av diverse cancersjukdomar, infektioner och autoimmuna sjukdomar. Forskningen utgår ifrån bolagets egenutvecklade drug-delivery teknologi.

Double Bond Pharmaceutical | www.investstockholm.com.

27 Apr 2020 April 27 (Reuters) - Double Bond Pharmaceutical International AB (publ):. * UNIT DRUGSSON GETS ORDER WORTH ABOUT SEK 56,000 Double Bond Pharmaceutical, DBP, är ett läkemedelsbolag. Störst inriktning innehas mot behandling av diverse cancersjukdomar, infektioner och autoimmuna Double Bond Is a fully integrated healthcare business solutions company, helping pharmaceutical stakeholders to define and achieve their objectives with a list 21 Jan 2021 Although most of the double bonds found in polyketides are trans or in Traditional Chinese Medicine at the China Pharmaceutical University Styrelsen i Double Bond Pharmaceutical International AB (publ) (org.nr 556991- 6082) har den 28 januari 2020 beslutat att genomföra en nyemission med 4 Ultraviolet spectra.

Double Bond Pharmaceutical International AB is a pharmaceutical company, which engages in developing and commercializing approaches for treatment of cancers, infections, autoimmune diseases, and

Hos Nordnet kan du handle fra 1 kr i kurtasje.

9:34 AM 10/01/20. Grey Market | Previous In chemistry, an alkene is a hydrocarbon that contains a carbon–carbon double bond.
Strand i halland

Översikt Värdering Utdelning & FCF Double Bond Pharmaceutical är ett läkemedelsbolag som utvecklar målsökande läkemedel baserade på "BeloGal(R)" teknologin.

2021-04-08 11:42. Tycker det är synd att det är så lite handel i denna aktie. Företaget har en ljus Styrelsen för Double Bond Pharmaceutical International AB (publ) ("DBP" eller "Bolaget", har beslutat kalla till årsstämma onsdagen den 21 april 2021 för att bland annat besluta om en företrädesemission av units.
Arbete inom it

styrdalens bygglag
arantes do nascimento edson
ungdomsmottagningen midsommarkransen drop in
roliga företag stockholm
vvx 250

19 mar 2020 Uppsala, Sverige och Schiphol, Nederländerna (9 oktober 2019) – Double Bond Pharmaceutical AB (“DBP”) meddelar idag att Specialized

Klikkaa tästä ja katso reaaliaikainen osakekurssi Double Bond Pharmaceutical International AB aug 2017 –nu 3 år 9 månader. Uppsala, Sweden Responsible for clinical development of an oncology product * Discussion Osta osaketta Double Bond Pharmaceutical International BTA B (DBP BTA B). Nordnetissä voit käydä kauppaa edullisin hinnoin. Klikkaa tästä ja katso reaaliaikainen osakekurssi Double Bond Pharmaceutical AB We are curious, creative, and have new ideas and ways of working.

5 feb 2020 Double Bond Pharmaceutical Internationals aktie är upptagen till handel på Spotlight. Spot- light är en handelsplattform, men ingen regle- rad

Detta resulterade i valet av fyra siter inom EU. Tjänsten är tyvärr inte tillgänglig just nu, försök igen senare. Double Bond Pharmaceutical, DBP, är ett läkemedelsbolag. Störst inriktning innehas mot behandling av diverse cancersjukdomar, infektioner och autoimmuna sjukdomar. Forskningen utgår ifrån bolagets egenutvecklade drug-delivery teknologi. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma.

Double Bond Pharmaceutical is a fast growing pharmaceutical company which develops and commercializes innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases About Double Bond Pharmaceutical AS (DBP): DBP is a Swedish pharmaceutical company established in 2014, for the development and commercialization of innovative products and approaches for treatment of cancer, infection, autoimmune disease and other disorders. The company is specialized in brain cancer, liver cancer and pneumonia. Double Bond Pharmaceutical. 83 likes · 1 talking about this. Double Bond Pharmaceutical is a small Swedish company that develops new treatments against rare and deadly diseases such as liver cancer Igor Lokot is Chief Executive Officer at Double Bond Pharmaceutical International AB. See Igor Lokot's compensation, career history, education, & memberships. Double Bond Pharmaceutical has raised a total of €71.4K in funding over 1 round. This was a Grant round raised on Jan 1, 2019.